Activity Details

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

• Incorporate patient preferences, values, and goals when developing a care plan
• Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
• Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to optimizing MDD treatment plans, thus increasing the proportion of patients with MDD who are able to achieve functional recovery.

Agenda

• Prevalence of major depressive disorder since COVID-19 pandemic
• Functional recovery and the importance of helping patients move beyond symptom remission
• Case study, functional recovery and shared decision-making
• Residual symptoms that frequently impede functional recovery
• Case study, residual symptoms
• Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

• Incorporate patient preferences, values, and goals when developing a care plan
• Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
• Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to optimizing MDD treatment plans, thus increasing the proportion of patients with MDD who are able to achieve functional recovery.

Agenda

• Prevalence of major depressive disorder since COVID-19 pandemic
• Functional recovery and the importance of helping patients move beyond symptom remission
• Case study, functional recovery and shared decision-making
• Residual symptoms that frequently impede functional recovery
• Case study, residual symptoms
• Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
• Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
• Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
• Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
• Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
• Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
• Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
• Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
• Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

• Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

• Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
• Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
• Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Activity Details

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
• Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
• Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.